Impact of Timing of Midazolam Administration on Incidence of Postoperative Nausea and Vomiting

• Status: Recruiting
• Trial end date: 2022-04-15
• Target enrollment: 0
• Participant gender: Female

Summary

Postoperative nausea and vomiting (PONV), defined as nausea and/or vomiting occurring within 24 hours after surgery, affects between 20% and 30% of patients, As many as 70% to 80% of patients at high risk may be affected. The etiology of PONV is thought to be multifactorial, involving individual, anaesthetic and surgical risk factors. PONV results in increased patient discomfort and dissatisfaction and in increased costs related to length of hospital stay. Serious medical complications such as pulmonary aspiration, although uncommon, are also associated with vomiting.

Patients with a higher risk of PONV often require a combination or multimodal approach of 2 or more interventions for effective risk reduction. Thus, researchers have explored additional nontraditional antiemetics, such as midazolam, that would aid in the multimodal prevention of PONV.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Benha University
• Treatments: Midazolam

Criteria

Inclusion Criteria:

• Female patients

• aged twenty to sixty years old

• The American Society of Anesthesiologists (ASA) physical status classification grade I or II

• Scheduled for laparoscopic gynecological surgeries under general anesthesia.

Exclusion Criteria:

• Patients who have gastrointestinal disorders,

• histories of PONV after a previous surgery,

• Renal or liver dysfunction,

• history of motion sickness,

• Have received any opioid, steroid, or antiemetic medication in the 24hs before surgery, and

• Pregnant or menstruating women.